Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (461-470 of 566) with videos related to

Pageof 57
Sort By:
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
American Journal of Hematology|October 26, 2017
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myelomaArjun Lakshman, Preet Paul Singh, S Vincent Rajkumar, et al.
American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.
Pageof 57

Showing results (461-470 of 566) with videos related to

Sort By:
Pageof 57
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
American Journal of Hematology|October 26, 2017
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myelomaArjun Lakshman, Preet Paul Singh, S Vincent Rajkumar, et al.
American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.
Pageof 57